RxDoctor Payments Data

Cameron Bonds, MD

Family Medicine · Sheffield, ALNPI 1699205989

Payments from drug & device makers

$5,558in general payments, 2019–2025

Across 373 payments — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Pfizer$579
  • AbbVie$558
  • Amgen$387
  • GSK$359
  • Boehringer Ingelheim$348
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$5,533100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,558 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$234,232
Medicare patients
696
Services billed
7,690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$75,081
JardianceEmpagliflozin75$74,990
EliquisApixaban63$69,548
FarxigaDapagliflozin Propanediol65$65,174
RybelsusSemaglutide26$61,698
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$43,659
JanuviaSitagliptin Phosphate47$34,924
MounjaroTirzepatide21$33,412
XareltoRivaroxaban43$33,178
Nurtec OdtRimegepant Sulfate26$26,424
LinzessLinaclotide35$25,425
QuliptaAtogepant16$17,473
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$17,109
Dexlansoprazole DrDexlansoprazole49$10,960
TradjentaLinagliptin15$10,735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,039$136,77982 claims
PfizerEliquis, Nurtec Odt$579$95,97289 claims
Boehringer IngelheimJardiance, Tradjenta$348$85,72590 claims
AstraZenecaFarxiga, Breztri Aerosphere$333$82,28390 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$359$57,00982 claims
AbbVieLinzess, Qulipta, Synthroid$558$45,746106 claims
MerckJanuvia$27$34,92447 claims
Lilly USA, LLCMounjaro$274$33,41221 claims
Johnson & JohnsonXarelto$207$33,17843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Sheffield

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →